Business Standard

Analysts positive on Jubilant Life despite 52% dip in Q1 profit; here's why

Barring unforeseen circumstances, the management expects strong performance in their Pharma, Life Science Ingredients, and Drug Discovery and Development Solutions business

The key positive for the quarter, according to analysts at JM Financials, was the management guiding for a double-digit revenue growth in the LSI business in FY21
Premium

The key positive for the quarter, according to analysts at JM Financials, was the management guiding for a double-digit revenue growth in the LSI business in FY21

SI Reporter New Delhi
Shares of Jubilant Life Sciences skid as much as 6.8 per cent to hit a low of Rs 773 on the BSE on Monday after the company's June quarter profit more-than-halved to Rs 88 crore.

The pharmaceutical firm's consolidated net profit came in at Rs 88.01 crore, down 52.42 per cent from Rs 184.98 crore reported in the year-ago period. Consolidated total revenue from the operations stood at Rs 1,892.92 crore for the quarter under review, as against Rs 2,181.86 crore for the same period a year ago.

"Overall, barring unforeseen circumstances, we expect strong performance in our Pharma, Life Science Ingredients

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in